Pgy 2 Program
Investigational Drugs and Research

About the PGY2 Investigational Drugs and Research Residency Program


PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.


The goal of the PGY2 Investigational Drugs and Research residency is to provide candidates with the specialized knowledge and skills to operate as an effective and expert practitioner in research pharmacy.   This will be accomplished through focused experiential rotations, a combination of didactic and hands-on learning, and an opportunity to further advanced the field through a research or quality improvement project.  Residents will participate in the operational aspects of research pharmacy, including budget preparation, feasibility analysis, investigational product management and the clinical aspects of safe management of clinical trial patients.  In addition, residents will have the opportunity to interact with world-renowned researchers in both oncology and non-oncology areas across the medical center.  By the end of their PGY-2 program, the resident will have the training required to seek a specialized research pharmacist position in a variety of settings including hospitals, academia and industry.

Residency Sites


The Ohio State University Wexner Medical Center (OSUWMC) is a 1,506 bed tertiary care medical center located in Columbus, Ohio. It is a multi-hospital delivery system recognized in 2022 as one of “America’s Best Hospitals” for excellence in 9 specialties by US News and World Report based on quality, outcomes, and reputation.

Read More

The James Cancer Hospital and Solove Research Institute

The Ohio State University Comprehensive Cancer Center – James Cancer Hospital will be the primary practice site for the Investigational Drugs and Research residency.  The James is ranked nationally as one of the top hospitals for cancer care, maintaining an “exceptional” rating – the highest descriptor given by the National Cancer Institute, and is the third largest cancer center in the nation.  Opened in December 2014, with 21 floors spanning 1.1 million square feet, the new James Cancer Hospital and Solove Research Institute revolutionizes the way cancer prevention and care are provided, with over 200 specialized oncologists and cancer researchers working side-by-side to unlock the mysteries of what causes cancer and, using those discoveries, transition from cancer treatment to cancer prevention.

University Hospital (UH)

University Hospital (UH) will serve as an additional site serving patients and research in non-oncologic disease states.  UH is our flagship hospital with over 900 beds and is a major referral center for patients throughout Ohio and the Midwest, and is one of the busiest kidney and pancreas transplant centers in the world. UH is also an international center for neuromodulation research and neurological care. In addition, UH is a level 1 trauma center in addition to being the American Burn Associated verified adult burn center for the region.

Key Rotations / Experiences

The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest.  The following is a list of the required learning experiences:

  • Orientation
  • Investigational Drug Service (IDS) Core
  • IDS Leadership
  • Clinical Trial Office
  • Clinical Trial Management Office
  • Office of Responsible Research Practices
  • Clinical Inpatient
  • Clinical Outpatient
  • Clinical Treatment Unit
  • Research Informatics
  • Drug Development Institute
  • Precepting
  • Teaching
  • Institutional Review Board
  • IDS Longitudinal
  • Clinical or Quality Research Project
  • Operational Staffing

Elective offerings may vary according to the interests of the resident.

Key Preceptors

Hallie Barr, PharmD, BCOP

Pharmacy Manager, Investigational Drug Service

Kelley Barley, PharmD

Research Pharmacist

Emily Harmon, PharmD

Research Pharmacist

Daniel Haas, MS, RPh

Research Pharmacist

Amanda Sabol, PharmD, BCPS

Research Pharmacist

Jennifer Severing, PharmD, BCPS

Research Pharmacist

Naomi Digiantonio, PharmD, BCPS

Generalist Pharmacist, Clinical Treatment Unit

Janinah Barreto, PharmD,MS, CPHIMS

Assistant Director, Pharmacy Informatics Clinical Apps

Jeffrey Patrick, PharmD

Director, Drug Development Institute

Sandra Meadows, MPH, CIP

Program Manager, Educational Programming and Regulatory Support

Office of Responsible Research Practices

Kristina Humphries

Assistant Director, Clinical Trials Office

OSU Comprehensive Cancer Center

Lisa Hafer, MPH, CCRP

Assistant Director-Operations, Clinical Trials Management Organization

Center or Clinical Research Management, College of Medicine

Benefits and Additional Requirements

Application Deadline:  January 9, 2023

We welcome applications from non-U.S. citizens who have a “green card” (permanent resident status) or a current visa valid through the entire duration of the residency program. The Ohio State University pharmacy residency programs are NOT able to sponsor visas for pharmacy residents (PGY1 or PGY2).

Start Date: July 1, 2023

Annual Salary- $50,500

Vacation Days- 10 days

Staffing Requirement- 20 weekends per year

Completion of a Major Research Project


Download PDF